Animal Research in Medical Sciences: Seeking a Convergence of Science, Medicine, and Animal Law

John J. Pippin

Physicians Committee for Responsible Medicine, jjpippin@sbcglobal.net

Follow this and additional works at: http://animalstudiesrepository.org/acwp_all

Part of the Animal Experimentation and Research Commons, Animal Studies Commons, and the Other Law Commons

Recommended Citation
ANIMAL RESEARCH IN MEDICAL SCIENCES:
SEEKING A CONVERGENCE OF SCIENCE, MEDICINE,
AND ANIMAL LAW

JOHN J. PIPPIN*

I. INTRODUCTION ................................................................. 469
II. THE LAW AS APPLIED TO ANIMAL RESEARCH ............... 470
III. ANIMAL USE IN MEDICAL SCIENCE RESEARCH .............. 474
   A. HIV/AIDS Vaccine Research ............................................. 475
   B. Stroke Research ................................................................. 477
   C. Neurological and Brain Research ................................. 479
   D. Menopausal Hormone Therapy Research ...................... 483
   E. Cancer Research .............................................................. 488
IV. ANIMAL USE IN DRUG DEVELOPMENT AND TESTING .......... 496
V. WHY ANIMAL RESEARCH IS A FAILED PARADIGM AND WHAT
   SHOULD BE DONE ............................................................... 504
VI. ANIMAL LAW SHOULD BETTER REFLECT ANIMAL RESEARCH
   REALITIES ......................................................................... 509

I. INTRODUCTION

As of April 2013, the Animal Legal Defense Fund lists 144 U.S. and
Canadian law schools that offer courses in animal law,¹ and 190 U.S. and
international student Animal Legal Defense Fund chapters.² This is
remarkable growth from only nine animal law courses available at U.S. and
Canadian law schools in 2001,³ and the emergence of an energized animal

---


As the intersection of animal law and animal research becomes congested, it is appropriate to establish the scientific context in which laws regarding the use and care of research animals will operate. There are at least three components of this context that set the terms of the debate: ethics, science, and the legal status of animals. The following discussion will not address ethics; not because it isn’t important, but because it exists along a spectrum of objective and subjective positions that are often unassailable by argument and data. I can assure you as a former animal researcher that even in the most compassionate hands, animal research is cruel, sad, and deadly for animals. The pro-research ethics argument can only be that this research is a “necessary evil” for the advancement of science and medicine, and thus worth the cost in animal misery.

It is my belief that it is not essential to engage the ethics argument because the science of animal research is more than sufficient to discredit the practice. If this is true—and as a former practitioner and longtime critic I fervently believe it is—then the animal research community must face the reality that when the “necessity” is not there, then only the “evil” remains. That is perhaps what will motivate the animal law community to help achieve a convergence of science, medicine, and animal law.

\section*{II. The Law As Applied to Animal Research}

explicitly or in practice. A very useful two-part review of the history of U.S. animal laws since 1972 is available.

Despite the large number of animal protection laws promulgated, the only federal statute that regulates the treatment of animals in research, exhibition, transport, and by dealers is the Animal Welfare Act (AWA), which was passed by Congress in 1966 and amended in 1970, 1976, 1985, 1990, 2002, 2007, and 2008; and enforced by the U.S. Department of Agriculture (USDA), Animal and Plant Health Inspection Service (APHIS), Animal Care Program (AC). The definition of animals covered by the AWA is restrictive and has become patchwork as amended over four decades:

The term “animal” means any live or dead dog, cat, monkey (nonhuman primate mammal), guinea pig, hamster, rabbit, or such other warm-blooded animal, as the Secretary may determine is being used, or is intended for use, for research, testing, experimentation, or exhibition purposes, or as a pet; but such term excludes (1) birds, rats of the genus Rattus, and mice of the genus Mus, bred for use in research, (2) horses not used for research purposes, and (3) other farm animals, such as, but not limited to livestock or poultry, used or intended for use as food or fiber, or livestock or poultry used or intended for use for improving animal nutrition, breeding, management, or production efficiency, or for improving the quality of food or fiber. With respect to a dog, the term means all dogs including those used for hunting, security, or breeding purposes.

As a result of this definition of animal, specifically as diminished by USDA regulation in 1971 and subsequently by congressional amendment of the AWA in 2002 to exclude birds, rats, and mice bred for research, about 95% of animals used for research in the U.S. are excluded from coverage under the AWA. Despite several lawsuits against the USDA and

---

establishment of standing for specific plaintiffs, “the courts allowed the USDA and industry to circumvent the will of Congress, leaving the AWA as a paper tiger.” Regulation guiding the interpretation and enforcement of the AWA, developed by AC, are published annually in the Code of Federal Regulations, Title 9, Chapter 1, and may be accessed on the USDA APHIS website.

In practice, enforcement of the AWA focuses on animal treatment rather than animal use, utilizes a checklist approach to assess compliance with specific elements of the AWA, and does not address the suitability or justification for animal use—a function AC reserves for institutional animal care and use committees. Thus, the AWA does not prohibit any research protocols from approval and implementation, no matter how useless, painful, or wasteful they are.

AC de-emphasizes penalties when enforcing the AWA, and minor violations are allowed to be corrected by a stated date without establishing a violation of the AWA. More serious “noncompliances” may generate a warning letter, and very serious or repeated violations may result in an investigation of the facility by the USDA’s Investigative and Enforcement Services (IES). When an IES investigation confirms the alleged AWA violation(s), civil penalties are typically applied, which may include fines of up to $10,000 per violation. Criminal penalties are also available to AC but are seldom employed.

Available remedies notwithstanding, AC has faced criticism that its enforcement of the AWA is weak and ineffective. The bar for receiving a fine or other penalty is high, fines are often redirected to the violating facilities, and settlements are encouraged that substantially discount fines, avoid federal charges, and allow the cited facilities to neither admit nor deny the alleged violations.

Periodic audits by the USDA Office of Inspector General (OIG) of AC enforcement of the AWA have been supportive of these criticisms and are quite critical of AC enforcement practices. The most recent OIG audit report broadly addressing AWA enforcement cited numerous serious deficiencies, including the following:

♦ Failure of AC’s Eastern Region to aggressively pursue “enforcement actions against violators of the AWA” despite recommendations from its facility inspectors.

---

14. Tischler, Part II, supra note 8, at 66.
Failure to use enforcement measures rather than repeated educational measures in addressing facility violations, thereby undermining the authority and damaging the morale of its Veterinary Medical Officers.

Failure to refer violators for investigation by the USDA IES as appropriate, and failure to implement the recommendations of the IES following investigations.

Failure to fine violators sufficiently (typically discounting fines by 75%), creating a climate in which “violators consider the monetary stipulation as a normal cost of conducting business rather than a deterrent for violating the law.”

Failure on the part of the USDA’s Veterinary Medical Officers to ensure that facilities provided them with basic data on the research facilities, such as “the number of animals used in research” and the number of “unexpected animal deaths.”

Failure on the part of Institutional Animal Care and Use Committees (IACUC) to effectively monitor animal care activities (veterinary care, review of painful procedures).

Failure on the part of IACUCs to ensure the use of nonanimal methodologies where such research avenues exist.17

USDA APHIS issued a lukewarm point-by-point response to the OIG audit report,18 and it is questionable whether substantive improvements have resulted from the audit report, which has no enforcement mandate.

Therefore, the only federal statute regulating the use and care of animals in research seems not to be up to the task. In an effort to improve AC facility inspections and prevent useless, unnecessary, and arguably illegal animal use under the auspices of the AWA, in September 2012 the Physicians Committee for Responsible Medicine (PCRM) petitioned for a meeting with the USDA Office of General Counsel (OGC). Among the claims stated by PCRM are that the USDA has broad authority to interpret and enforce the statute, that the agency would better serve its enforcement role by expanding its interpretation to permit denial of animal use protocols when valid alternatives to animal use are available, and justification for disregarding those alternatives is inadequate.19 The agency has previously opined that “[t]he AWA does not permit APHIS to interrupt the conduct of

18. See id. at 45–51 (Exhibit E).
actual research or experimentation.”20 But PCRM believes the more expansive interpretation proposed is within the USDA’s broad interpretive authority and allows better implementation of the AWA. Nevertheless, in December 2012 the USDA OGC confirmed its previous opinion, and the proposed meeting did not occur.

III. ANIMAL USE IN MEDICAL SCIENCE RESEARCH

Proponents of animal experimentation often make the sweeping claim that almost every major advance in human medicine during the last century has been attributable to animal research. This claim was first reported—without supporting citation—by the U.S. Public Health Service in 1994,21 and it has become almost rote among researchers, research institutions, and many funding agencies. But the claim has crumbled under scrutiny. Perhaps most succinctly, Robert Matthews’s analysis demonstrates that this claim has not been (and cannot be) validated, and he further describes the inadequacies of the predictive value and evidential weight from animal experimentation.22

It may reasonably be stated that most medical advances have included animal experimental use; for decades this has been the default approach. But it has not been demonstrated that such animal use has been essential or even reliable for medical advancement. Thus, the claim that animal research contributes importantly to human health is analogous to claiming that white coats cure patients—yes, doctors wear white coats, but the white coats are not essential for the practice of medicine. Animal research occurs in the medical sciences, but it is not essential for favorable human outcomes. In fact, the unreliability of animal research and its many wrong turns have frequently delayed or derailed medical advances and exposed patients to ineffective and dangerous treatments.

Numerous reports demonstrate this unreliability of animal experimentation for investigation of human diseases and the development of safe and effective treatments, and describe the suitability of nonanimal

methods to replace them. Persistence of many scientists’ belief in the animal experimentation paradigm despite the preponderance of contrary evidence, and their resistance to change, has been attributed to technological and institutional lock-in.

Unknown to most of the public, entire fields of medical discovery have derived little or nothing of value for humans from decades of animal experimentation. Many of the major causes of morbidity and mortality among humans are eye-opening examples of this failure of animal experimentation, including but not limited to HIV/AIDS, stroke, cancers, menopausal hormone therapy, spinal cord injury (paralysis); and numerous other neurological, immunological, cardiovascular, and endocrine (most prominently diabetes mellitus) diseases.

### A. HIV/AIDS Vaccine Research

Although to date, more than eighty-five HIV/AIDS vaccines have been both safe and effective in animal studies (predominantly using nonhuman primates), none has been successful in more than 200 human trials either for the prevention or treatment of HIV infection. As of April 2013, the National Library of Medicine website, ClinicalTrials.gov, lists 130 human trials of preventive HIV vaccines and 54 human trials of therapeutic HIV vaccines. None of these trials has demonstrated a conclusive benefit either

---


for prevention or control of HIV infection, and no HIV vaccine has been approved for human use.

In fact, only a handful of vaccine candidates have even progressed to phase III clinical trials, the final step before submission for FDA approval. The vast majority of vaccines tested on humans have failed during phase I and II trials designed to test vaccine safety and efficacy on smaller numbers of participants. Among the few vaccines that have reached phase III, the results from perhaps the two most-highly-touted vaccines are illustrative.

The Step Study was the culmination of more than two decades of basic science research and failed human trials, and was viewed as employing a vaccine that had surmounted previous shortcomings believed to have prevented successful translation of animal results to humans. The study of 3,000 participants at high risk for HIV infection was designed to assess the ability of the Merck vaccine to prevent HIV infection and its effectiveness in controlling the viral burden among participants who contracted HIV during the study. The Step Study was halted after the first interim data analysis confirmed that the vaccine did not prevent HIV infection or reduce viral burden.

The HIV/AIDS research community was rocked by the additional finding that participants who received the vaccine had a higher rate of HIV infection than those who received the placebo. A four-year follow-up study of infected participants documented a persistent 40% increased risk for HIV infection among vaccine recipients compared to placebo recipients.

The ALVAC-AIDSVAX clinical trial, conducted by the U.S. Army and the Thai government, included 16,402 men and women in Thailand. Its goals were to assess the vaccine’s ability to prevent HIV infection and its effectiveness in controlling the viral burden among those who contracted HIV during the trial. No statistically significant decrease in HIV infections

---

29. Id. at 1, 3–5.
30. Id. at 1, 10.
31. Id. at 8.
34. Id.
was seen among vaccinated participants, and no benefit in control of viral burden was seen in the three-and-a-half year trial period.\textsuperscript{35} A subsequent study designed to assess the longer-term effect of the vaccine on viral burden and disease progression among 114 participants who contracted HIV during the initial trial showed no benefits for the vaccine after two additional years.\textsuperscript{36}

At an urgent HIV/AIDS summit convened in March 2008 after the failure of the Step Study, summit co-chair Warner C. Greene, M.D. from the University of California, San Francisco, stated: “Despite hundreds and hundreds of millions of dollars, the reality in 2008 is that an HIV vaccine clearly remains beyond our grasp.”\textsuperscript{37} The National Institute of Allergy and Infectious Diseases website explains precisely why this is still true five years later: “It has been difficult to study HIV because the virus exclusively infects and causes disease in humans. As a result, there is no ideal animal model that can imitate the natural history and pathogenesis of HIV/AIDS in the human body.”\textsuperscript{38}

B. Stroke Research

Stroke due to cerebrovascular disease is the number-four killer of Americans, causing nearly 130,000 deaths a year.\textsuperscript{39} About 90\% of strokes are caused by atherosclerosis and thrombosis in blood vessels supplying the brain.\textsuperscript{40} Animal research, predominantly using rodents but also larger mammals such as rabbits and nonhuman primates, has for decades been the default scientific approach to studying the human disease and developing stroke treatments.\textsuperscript{41}

\begin{itemize}
  \item \textsuperscript{35} Id. at 2209.
  \item \textsuperscript{36} Follow-up Study to RV144 HIV Vaccine Trial Shows No Effect on Disease Progression in Infected Volunteers, U.S. MILITARY HIV RES. PROGRAM (Sept. 16, 2011), http://www.hivresearch.org/news.php?NewsID=220.
  \item \textsuperscript{40} Véronique L. Roger et al., Heart Disease and Stroke Statistics—2012 Update: A Report from the American Heart Association, 125 CIRCULATION e2, e68 (2012), available at http://circ.ahajournals.org/content/125/1/e2.full.pdf+html.
  \item \textsuperscript{41} See Juliana B. Casals et al., The Use of Animal Models for Stroke Research: A Review, 61 COMP. MED. 305, 307 (2011), available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155396/pdf/cm2011000305.pdf; see also
\end{itemize}
Numerous reviews have documented the futility of animal research for developing treatments to reverse or ameliorate human stroke. Malcolm R. Macleod and colleagues reported more than 4,000 studies identifying more than 700 successful neuroprotective drugs in animal experiments. Macleod subsequently reported that every one of about 150 human drug trials for stroke has failed to improve survival, and he estimated that about 250,000 animals had been used between 1985 and 2005 in this futile effort.

In a large meta-analysis of 525 publications regarding sixteen therapeutic interventions tested in animal studies, only ten studies (2%) correctly reported no overall benefit for the tested treatment, and only six studies did not report at least one statistically significant favorable finding. Yet the only intervention that provided short-term symptomatic improvement for stroke patients was recombinant tissue plasminogen activator, which was already in clinical use for myocardial infarction, can only be given to about 5% of stroke patients, and does not improve survival. As succinctly stated by Annals of Neurology editor S. Claiborne Johnston in 2006: “Ischemic stroke is a case study in failed translation.”


C. Neurological and Brain Research

Spinal cord injuries (SCI) with paralysis are devastating events that have proven resistant to reversal or improvement despite decades of animal experiments primarily using rodents, as well as cats, dogs, and nonhuman primates. Akhtar and colleagues have provided a comprehensive review of this topic, addressing mechanistic, anatomical, and biological reasons for the inability of animal models of SCI to translate to human benefit. Their subsequent review of methylprednisolone details the failures of this most-tested therapy for SCI.

Every one of ten randomized prospective controlled trials involving 2,717 patients, and numerous other clinical trials of treatments for acute SCI that were successful in animals, have failed to confirm benefits for humans. Charles H. Tator, M.D., Ph.D., section editor of the Journal of Neurotrauma, concluded in 2006: “The field of spinal cord injury (SCI) is remarkable for the high number of treatment trials in humans. Unfortunately, none has produced a major improvement in neurological recovery or a meaningful increase in function, although much effort and resources have been expended.” Six years later, in his extensive updated review of SCI animal research, Dr. Tator and colleagues repeated that “no agents that produce major benefit have been proven to date.”

In the related field of traumatic brain injury (TBI), the failure of animal experimentation is equally evident. TBI is the most common cause of morbidity and mortality worldwide in persons less than forty-five years old, largely due to the proliferation of automobile travel and constant warfare on the planet. Animal studies have been unable to approximate

---

51. Tator, supra note 50, at 957.
the complexities of human TBI,\(^\text{55}\) and instead, researchers have relied on animal models that are affordable, simple, and widely applicable,\(^\text{56}\) rather than closely representative of human TBI.

Although rodents are most commonly used to model human TBI, researchers acknowledged the severe restrictions imposed by the major brain and spinal cord anatomical and structural differences between rodents and humans, as well as the large discrepancies between rodent and human physiological and behavioral responses to neurological trauma.\(^\text{57}\) Even nonhuman primate studies have been discordant with the mechanisms and outcomes of human TBI, and the use of any other species is also known to produce immutable differences in injury outcomes.\(^\text{58}\)

There appears to be general surrender among researchers regarding the translation of animal research findings to human TBI\(^\text{59}\)—which is highlighted by the 2010 report by Maas and colleagues of twenty-seven phase III clinical trials and six unpublished trials that universally failed to show benefits for TBI patients, despite showing benefit in animal studies.\(^\text{60}\) The role of in vitro models of TBI has gained favor among some researchers.\(^\text{61}\) These models are usually compared to the discredited animal models of TBI rather than to human TBI pathology, which complicates the assessment of their relevance for humans.\(^\text{62}\)

Numerous other neuroscience research areas have also been unproductive in terms of human benefit, despite many years of animal experimentation. As of 2005, more than fifty publications reported therapeutic agents that prolonged survival in the standard SOD1 mouse

---

55. See generally D.M. Morales et al., Experimental Models of Traumatic Brain Injury: Do We Really Need to Build a Better Mousetrap?, 136 NEUROSCIENCE 971, 972 (2005) (examining many animal studies and concluding that no one animal study can reproduce the entire spectrum of human TBI); see also Finnie & Blumbergs, supra note 54, at 679 (“No single animal model can reliably replicate the full spectrum of human TBI.”).


58. See Finnie & Blumbergs, supra note 54, at 679.


model for amyotrophic lateral sclerosis (ALS). Yet not a single phase III clinical trial in four decades has shown any convincing benefit for ALS patients. Benatar’s 2007 review detailed the internal inconsistencies and lack of translation for eighty-five ALS animal studies reporting seventy-eight different treatment modalities. Traynor and colleagues identified 113 promising ALS drugs from animal studies and early stage clinical trials, but none of these translated to patient benefits.

Only one drug, riluzole, is approved for use in ALS in the United States, and that drug may only marginally slow disease progression for some patients while not prolonging survival. The animal studies that led to clinical testing of riluzole could not be replicated by Scott and colleagues, who concluded that the purported benefit of riluzole was merely statistical noise. Most recently, the much-anticipated EMPOWER clinical trial of Biogen Idec’s dexpramipexole, which had “shown neuroprotective properties in multiple in vitro and in vivo studies,” failed to demonstrate any benefit among 943 ALS patients for improving either function or survival.

Animal research has also produced no effective treatments for the other major motor neuron diseases, including primary lateral sclerosis, progressive muscular atrophy, spinal muscular atrophy, progressive bulbar palsy, and pseudobulbar palsy. The sad reality is that spontaneous symptom regression and arrested disease progression are more common than any treatment benefits for ALS and the other motor neuron diseases.

---


64. See Michael Benatar, Lost in Translation: Treatment Trials in the SOD1 Mouse and in Human ALS, 26 NEUROBIOLOGY DISEASE 1, 3 (2007).


Experimental autoimmune encephalitis (EAE) is the animal model pathology developed to replicate human multiple sclerosis (MS), using primarily mice but also rats, guinea pigs, rabbits, and nonhuman primates. Animal research reviews have reported that over the past few decades, literally thousands of drugs have been used successfully in EAE animals, and it is possible to control immune-mediated disease at any point during the relapsing disease process in animal models. However, these ubiquitous animal model successes are incapable of predicting benefits for patients, and the mantra among some EAE researchers has become, “Everything stops EAE, nothing cures MS.”

Some of these treatments actually worsen MS or cause severe and sometimes lethal adverse effects undetected in animal studies, including liver failure, heart damage, infertility, acute myelogenous leukemia, and progressive multifocal leukoencephalopathy. Even the few drugs that have been shown to decrease relapse frequency for relapsing-remitting MS patients have not been consistently effective in modifying MS symptoms and disease progression. Additionally, there is no effective treatment for the progressive forms of MS.

Animal research studying the related dementias Alzheimer disease (AD) and frontotemporal dementia (FTD) has employed genetically modified mouse models that attempt to replicate the putative etiology and hallmarks of AD in humans, brain deposition of amyloid-β peptide aggregates and tau protein tangles. AD is the most common cause of dementia in older patients, while FTD causes half of dementias in patients.

---

70. Hanna M. Vesterinen et al., Improving the Translational Hit of Experimental Treatments in Multiple Sclerosis, 16 MULTIPLE SCLEROSIS 1044, 1044–45 (2010).
71. See generally Gareth Pryce et al., Autoimmune Tolerance Eliminates Relapses but Fails to Halt Progression in a Model of Multiple Sclerosis, 165 J. NEUROIMMUNOLOGY 41 (2005) (showing the poor correlation between EAE models in rodents and the progression of MS).
73. See Alastair Compston & Alasdair Coles, Multiple Sclerosis, 359 LANCET 1221, 1228 (2002); Giancarlo Comi, Treatment of Multiple Sclerosis: Role of Natalizumab, 30 NEUROLOGICAL SCI. S155, S156 (Supp. II 2009); see generally Helen Tremlett & Joel Oger, Hepatic Injury, Liver Monitoring and the Beta-Interferons for Multiple Sclerosis, 251 J. NEUROLOGY 1297 (2004).
74. See Heather J. MacLean & Mark S. Freedman, Multiple Sclerosis: Following Clues from Cause to Cure, 8 LANCET NEUROLOGY 6, 7 (2009).
75. See Todd E. Golde, The Aβ Hypothesis: Leading Us to Rationally-Designed Therapeutic Strategies for the Treatment or Prevention of Alzheimer Disease, 15 BRAIN PATHOLOGY 84, 85 (2005); see generally Todd E. Golde et al., Targeting Aβ and Tau in Alzheimer’s Disease: An Early Interim Report, 223 EXPERIMENTAL NEUROLOGY 252 (2010).
younger than sixty years.\textsuperscript{77} No therapies have been developed that prevent, ameliorate, slow progression, affect mortality, or provide cure for patients with AD or FTD,\textsuperscript{78} and some commonly used drugs can worsen functional impairment and hasten cognitive decline.\textsuperscript{79} Several of the interspecies barriers that explain these failures have been reviewed.\textsuperscript{80}

All of the amyloid-β targeted drugs to reach phase III clinical trials have failed to impact symptoms or outcomes.\textsuperscript{81} The latest and most hopeful drug tested in AD patients is Dimebon (latrepirdine), which showed no evidence for efficacy in a phase III trial involving 598 patients\textsuperscript{82} after being hyped with the headline “Dimebon shines as Alzheimer’s therapy”\textsuperscript{83} following a phase II trial involving 155 patients.\textsuperscript{84} Consistent failure to translate animal-derived treatments aimed at preventing or removing pathological brain protein accumulations in patients, combined with other inconsistencies, puts the AD amyloid protein hypothesis in jeopardy, and thus potentially discredits more than two decades of AD animal research.\textsuperscript{85}

D. Menopausal Hormone Therapy Research

For six decades after the 1942 FDA approval of conjugated equine estrogen (Premarin) for treatment of menopausal symptoms such as hot flashes, mood swings, and disordered sleep, women were informed and reassured about the therapeutic and preventive health properties of estrogen

\textsuperscript{77} Id.; see also Carlo Ballatore et al., Tau-Mediated Neurodegeneration in Alzheimer’s Disease and Related Disorders, 8 NATURE REV. NEUROSCIENCE 663, 663 (2007).

\textsuperscript{78} See Götz & Ittner, supra note 76, at 541; David M. Holtzman, Moving Towards a Vaccine, 454 NATURE 418, 418 (2008); Lon S. Schneider et al., Treatment with Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer’s Disease Neuroimaging Initiative, 68 ARCHIVES NEUROLOGY 58, 64 (2011).

\textsuperscript{79} Schneider et al., supra note 78, at 58, 60, 62.

\textsuperscript{80} See generally Hugo Geerts, Of Mice and Men: Bridging the Translational Disconnect in CNS Drug Discovery, 23 CNS DRUGS 915 (2009).

\textsuperscript{81} Eric Karran et al., The Amyloid Cascade Hypothesis for Alzheimer’s Disease: An Appraisal for the Development of Therapeutics, 10 NATURE REV. DRUG DISCOVERY 698, 698 (2011).


replacement. After it was reported in 1975 that unopposed estrogen therapy caused a several-fold increase in endometrial cancers, and the next year that estrogen use may increase breast cancer risk, estrogen prescriptions plummeted. But it was soon found that adding progestin to estrogen maintained estrogen’s relief of menopausal symptoms and eliminated the increased risk for endometrial cancer. This combination was used for nearly two decades, and a fixed-dose estrogen and progestin combination pill (Prempro) was approved by the FDA in 1995. At the turn of the millennium, menopausal hormone therapy (MHT), formerly known as hormone replacement therapy, using Premarin and Prempro generated more than sixty-five million prescriptions annually, and more than six million American women were taking an estrogen and progestin combination drug.

Preclinical animal experiments indicated to Wyeth Pharmaceuticals (part of Pfizer, Inc. since 2009) that estrogen and the estrogen and progestin combination were protective regarding heart and vascular diseases, and the company pursued numerous experiments in various animal species to identify mechanisms and outcomes for this suspected protective effect. Using a diet-induced atherosclerosis nonhuman primate model (cynomolgus macaque) and postmortem assessment, Adams and colleagues found that estrogen with or without progestin reduced the development of coronary atherosclerosis by about half over thirty months. The same researchers demonstrated links between decreased atherosclerosis in the high-estrogen state of pregnancy and increased atherosclerosis in the low-estrogen state of surgical menopause, leading to the conclusion that estrogen is protective regarding atherosclerosis. A subsequent coronary arteriography study in cynomolgus macaques suggested that the protective effect of


88. Id.

89. Michael R. Adams et al., Inhibition of Coronary Artery Atherosclerosis by 17-Beta Estradiol in Ovariectomized Monkeys, 10 ARTERIOSCLEROSIS, THROMBOSIS, & VASCULAR BIOLOGY 1051, 1051, 1056 (1990).


estrogen is mediated by improved vascular function,\textsuperscript{92} consistent with an earlier study that showed similar results in baboons.\textsuperscript{93}

Clarkson and colleagues demonstrated a protective effect of estrogen for coronary artery atherosclerosis\textsuperscript{94} and carotid artery atherosclerosis\textsuperscript{95} in postmenopausal cynomolgus macaques,\textsuperscript{96} and later showed the same protective effect for coronary atherosclerosis in postmenopausal long-tailed macaques.\textsuperscript{97} Other beneficial direct and mediated vascular effects of estrogen related to lowering cardiovascular risk have been demonstrated in rabbits,\textsuperscript{98} mice,\textsuperscript{99} rats,\textsuperscript{100} cows,\textsuperscript{101} and nonhuman primates.\textsuperscript{102}

\begin{itemize}
\item \textsuperscript{92} J. Koudy Williams et al., \textit{Estrogen Modulates Responses of Atherosclerotic Coronary Arteries}, 81 \textit{CIRCULATION} 1680, 1680, 1683 (1990).
\item \textsuperscript{93} Alan L. Lin et al., \textit{Estrogen Mediates Responses of Atherosclerotic Human Coronary Arteries}, 6 \textit{ARTERIOSCLEROSIS, THROMBOSIS, & VASCULAR BIOLOGY} 495, 495 (1986).
\item \textsuperscript{94} Thomas B. Clarkson et al., \textit{A Comparison of Tibolone and Conjugated Equine Estrogens Effects on Coronary Artery Atherosclerosis and Bone Density of Postmenopausal Monkeys}, 86 \textit{J. CLINICAL ENDOCRINOLOGY & METABOLISM} 5396, 5401 (2001).
\item \textsuperscript{95} Thomas B. Clarkson et al., \textit{Comparison of Tibolone and Conjugated Equine Estrogens Effects on Carotid Artery Atherosclerosis in Postmenopausal Monkeys}, 33 \textit{STROKE} 2700, 2702 (2002).
\item \textsuperscript{96} Adams et al., \textit{supra} note 91, at 192 (“Socially dominant intact females were protected against advanced atherosclerotic lesions (plaque) of the coronary arteries, while subordinate females and ovariectomized females were not.”).
\item \textsuperscript{97} Susan E. Appt et al., \textit{Low Dose Estrogens Inhibit Coronary Artery Atherosclerosis in Postmenopausal Monkeys}, 55 \textit{MATURES} 187, 187–88 (2006) (“[M]onkeys treated with low dose CEE had marked reductions in coronary artery atherosclerosis plaque extent (intimal area) in all three main coronary arteries.”).
\item \textsuperscript{100} See, e.g., Chang Wen-Chang et al., \textit{Stimulation of Prostacyclin Biosynthetic Activity by Estradiol in Rat Aorta Smooth Muscle Cells in Culture}, 619 \textit{BIOCHIMICA ET BIOPHYSICA ACTA} 107 (1980); Grace M. Fischer, \textit{In Vivo Effects of Estradiol on Collagen and Elastin Dynamics in Rat Aorta}, 5 \textit{ENDOCRINOLOGY} 1227, 1227, 1231 (1972).
\item \textsuperscript{101} John C. Beldekas et al., \textit{Effects of 17β-Estradiol on the Biosynthesis of Collagen in Cultured Bovine Aortic Smooth Muscle Cells}, 20 \textit{BIOCHEMISTRY} 2162, 2162 (1981).
\end{itemize}
As if to confirm the extensive animal studies, the Nurses’ Health Study, an observational study of 32,317 postmenopausal nurses, identified a protective effect of estrogen for heart disease. However, contemporaneous data from a much smaller cohort of women in the Framingham Heart Study reported opposite effects of estrogen for heart disease risk. A ten-year follow-up report from the Nurses’ Health Study reiterated the decreased heart disease risk with estrogen therapy for a larger cohort of 48,470 postmenopausal nurses, and this outcome was also supported by other observational studies. These studies are in sharp contrast to the increased heart disease risk seen in the Framingham Heart Study, and also contrast the failure of Premarin or Prempro to prevent coronary artery disease progression in the Estrogen Replacement and Atherosclerosis Trial.

Despite the lockstep uniformity of cardiovascular benefits in numerous mechanistic and outcome-focused animal studies of MHT, and despite the marked preponderance of confirmatory outcomes in observational clinical studies of MHT, all of these findings were wrong. And the consistency of animal studies of MHT in showing opposite effects, as compared to the effects in prospective clinical trials of postmenopausal women, is a strong indictment of the animal research paradigm.

Though the noted Framingham Heart Study results raised a red flag, the first major blow to the animal research results came from the randomized prospective Heart and Estrogen/Progestin Replacement Study (HERS) reported in 1998. HERS demonstrated no protection from heart attacks and cardiac deaths for estrogen/progestin therapy among 2,763 women with coronary heart disease.\textsuperscript{108} The Women’s Health Initiative (WHI) clinical trials of MHT further unraveled the purported cardiovascular protective benefits of MHT with word of the premature termination of the WHI estrogen and progestin trial in 2002. Designed to evaluate the effects of Prempro on the incidence of cardiovascular disease, cancers, and bone fractures, this landmark trial of 16,608 postmenopausal women was halted by its data and safety monitoring board due to increased risk for breast cancer among MHT recipients.\textsuperscript{109}

Complete data analysis at mean 5.2 years of follow-up confirmed 26% increased breast cancer risk, but also identified increased risks of 29% for coronary heart disease, 41% for stroke, 107% for deep vein thrombosis, and 113% for pulmonary embolism.\textsuperscript{110} All findings were confirmed in subsequent intermediate-term data analyses.\textsuperscript{111}

The parallel WHI Premarin study of 10,739 women with hysterectomies also was terminated prematurely due to increased stroke risk, and data analysis showed no cardiovascular protection from estrogen.\textsuperscript{112} In addition, the risks for hormone-related breast cancer, thrombosis, and pulmonary embolism were further confirmed in the UK Million Women Study.\textsuperscript{113} The preponderance of failed estrogen and


\textsuperscript{109} See Writing Grp. for the Women’s Health Initiative Investigators, \textit{Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial}, 288 JAMA 321, 321 (2002).

\textsuperscript{110} Id. at 326.


\textsuperscript{113} See Million Women Study Collaborators, \textit{Breast Cancer and Hormone-Replacement Therapy in the Million Women Study}, 362 LANCET 419, 419 (2003); see also S. Sweetland et al., \textit{Venous Thromboembolism Risk in Relation to Use of Different Types of Postmenopausal
The failure of MHT to prevent or mitigate cardiovascular disease has been cemented by a meta-analysis published shortly after the initial WHI estrogen and progestin study,115 a 2010 analysis of continued coronary heart disease risk among WHI participants,116 a 2012 systematic review of MHT studies published since 2002,117 and the updated U.S. Preventive Services Task Force 2013 guidelines for MHT.118 There can be little doubt that consistently misleading animal research results contributed to decades of inappropriate MHT, thereby causing substantial morbidities and mortality for postmenopausal women.

E. Cancer Research

The use of animals to investigate human cancers and to develop cancer treatments has been unreliable and sometimes damaging to patients. This is perhaps most succinctly explained by former U.S. National Cancer Institute director Richard Klausner, M.D., who stated in 1998: “The history of cancer research has been a history of curing cancer in the mouse. We have cured mice of cancer for decades—and it simply didn’t work in humans.”119 The clinical failure rate of cancer drugs developed from animal research is at least 95%, higher than for any other disease category.120 With rare exceptions, such as the success of Gleevec (imatinib) in treating chronic
myelogenous leukemia patients. Dr. Klausner’s conclusion is just as true fifteen years later.

Since President Richard Nixon signed the National Cancer Act in December 1971, stating the goal of curing cancer by the nation’s bicentennial five years later, more than a quarter trillion dollars has been spent to investigate and develop treatments for cancers. Today, the annual budget of the U.S. National Cancer Institute exceeds five billion dollars, and billions more are spent annually through other federal and state agencies, research facilities, private and charitable organizations, and pharmaceutical companies.

During the first two decades of Nixon’s program (dubbed the “war on cancer”), U.S. age-adjusted cancer mortality increased by 8%—twice the increase that occurred in the previous two decades. The administrator of the program, John C. Bailar III, M.D., reported in 1986 that “some 35 years of intense effort focused largely on improving treatment must be judged a qualified failure,” a conclusion he repeated more than a decade later. Recognizing the failed approach directed primarily toward animal research and drug development, Dr. Bailar noted that improvements in cancer mortality were attributable to prevention and early detection, and concluded: “The most promising approach to the control of cancer is a national commitment to prevention, with a concomitant rebalancing of the focus and funding of research.”

Indeed, of the three determinants of cancer mortality—prevention, early detection, and treatment—cancer treatment has contributed least to improved outcomes. Prevention efforts such as smoking cessation, dietary improvements, and physical activity have decreased the incidence of

---

121. See infra text accompanying notes 149–50.
127. Id. at 1569.
128. See Cutler, supra note 124, at 4; Bailar III & Smith, supra note 125, at 1231; Bailar III & Gornik, supra note 126, at 1573.
new cancer diagnoses for both men and women.\textsuperscript{129} Screening for breast,\textsuperscript{130} cervical,\textsuperscript{131} and colorectal\textsuperscript{132} cancers has contributed to better patient outcomes with early intervention. Other than for those fortunate patients for whom cancer is localized and initial treatment is curative, however, treatments for established cancers have seldom led to significant improvements in survival, and only rarely to cures.

Though overall U.S. cancer death rates are only about 5% lower in the last six decades,\textsuperscript{133} there has been a 20% decline in age-adjusted cancer mortality since the peak mortality year of 1991, predominantly due to prevention and screening efforts.\textsuperscript{134} And with few exceptions—such as some childhood cancers, testicular cancer, and Hodgkin disease—metastatic cancer may be slowed but remains incurable, even with the advent of the latest generation of targeted cancer drugs.\textsuperscript{135}

Standard xenograft models of human cancers, in which human cancer cells are transplanted beneath the skin of rodents, have been reported to have “few predictive achievements and many notable failures,” and it is acknowledged that “many agents that show consistent and potent anticancer activity in specific xenograft models prove to be of limited use in the therapy of human cancer.”\textsuperscript{136} These and other animal models of cancer have also fared poorly when compared to research using human cancer cell lines. A National Cancer Institute of Canada study of thirty-one cancer drugs found that human cancer cell lines were superior to the two most prominent

\begin{itemize}
\item \textsuperscript{132} See Evelyn P. Whitlock et al., \textit{Screening for Colorectal Cancer: A Targeted, Updated Systematic Review for the U.S. Preventive Services Task Force}, 149 \textit{ANNALS INTERNAL MED.} 638, 638 (2008); Amir Qaseem et al., \textit{Screening for Colorectal Cancer: A Guidance Statement from the American College of Physicians}, 156 \textit{ANNALS INTERNAL MED.} 378, 378 (2012).
\item \textsuperscript{134} Rebecca Siegel et al., \textit{Cancer Statistics, 2013}, 63 \textit{CA: CANCER J. FOR CLINICIANS} 11, 11 (2013); Cutler, supra note 124, at 4.
\item \textsuperscript{135} See Editorial, \textit{The End of the Beginning?}, 5 \textit{NATURE REV. DRUG DISCOVERY} 705 (2006).
\end{itemize}
mouse models for predicting drug efficacy in clinical trials,\textsuperscript{137} and the standard mouse models have been widely discredited as a means for studying and treating human cancers.\textsuperscript{138} The U.S. National Cancer Institute recognized this problem more than thirty years ago and developed the DTP Human Tumor Cell Line Screen, a panel of sixty human tumor cell lines, to replace unreliable animal testing for identification of drugs with anti-tumor effects.\textsuperscript{139}

In addition to displaying poor translation to human medicine, animal research regarding cancer has not even been reproducible, thus unmasking the unreliability of the laboratory research and its inapplicability to the care of cancer patients. Begley and Ellis reported that only six of fifty-three selected landmark preclinical cancer studies could be duplicated by Amgen scientists.\textsuperscript{140} Asadullah and colleagues reported that fewer than one-fourth of forty-seven early-stage cancer projects at Bayer HealthCare were reproducible, and that nearly two-thirds of those projects were either scrapped or markedly delayed when the preclinical research could not be validated.\textsuperscript{141} Some of this irreproducible research had stimulated numerous secondary publications that built on the false results. Alarmingly, related clinical studies subjected cancer patients to treatments that had little chance to succeed.\textsuperscript{142} And while targeted cancer treatments had unpredictable and erratic results, simply changing housing conditions for mice reportedly reduced the sizes of melanomas and colon cancers by as much as three-fourths.\textsuperscript{143}

Many reasons other than poor reproducibility have been documented for the failure of the animal research paradigm for the study of human

\begin{itemize}
  \item \textsuperscript{138} Ken Garber, \textit{Realistic Rodents? Debate Grows Over New Mouse Models of Cancer}, 98 \textit{J. NAT’L CANCER INST.} 1176, 1176 (2006); \textit{The End of the Beginning?}, supra note 135, at 705; Edward A. Sausville & Angelika M. Burger, \textit{Contributions of Human Tumor Xenografts to Anticancer Drug Development}, 66 \textit{CANCER RES.} 3351, 3351 (2006); Voskoglou-Nomikos et al., \textit{supra} note 137, at 4227, 4232.
  \item \textsuperscript{140} C. Glenn Begley & Lee M. Ellis, \textit{Raise Standards for Preclinical Cancer Research}, 483 \textit{NATURE} 531, 532 (2012).
  \item \textsuperscript{141} See Florian Prinz et al., \textit{Believe It or Not: How Much Can We Rely on Published Data on Potential Drug Targets?}, \textit{NATURE REV.: DRUG DISCOVERY} (Sept. 2011), http://www.nature.com/nrd/journal/v10/n9/full/nrd3439-c1.html.
  \item \textsuperscript{142} Begley & Ellis, \textit{supra} note 140, at 532.
  \item \textsuperscript{143} See Lei Cao et al., \textit{Environmental and Genetic Activation of a Brain-Adipocyte BDNF/Leptin Axis Causes Cancer Remission and Inhibition}, 142 \textit{CELL} 52, 52, 62 (2010).
\end{itemize}
cancers. No animal models replicate the tumors that are grafted onto them in terms of tumor architecture, growth rate, metastatic potential, interaction with nonhuman tissue elements, or response to drugs.\textsuperscript{144} Because rodent models are intentionally immune-deficient to permit unregulated tumor growth, they present an unrealistic biological milieu and are unable to replicate the behaviors of tumors in a patient or the combined effects of the human immune system and cancer drugs. And though scientists and physicians have long known that 90\% of cancer deaths are due to metastatic tumor spread,\textsuperscript{145} the mechanisms and treatments of metastatic cancer are rarely addressed in animal models due to the complexity involved.

Many human tumor cell lines used in animal studies are inadequately characterized or internally inconsistent, thus introducing irreproducibility even before animal studies are conducted.\textsuperscript{146} And the functions of human cancer-promoting or cancer-suppressing genes transferred into animals are often different in direction and magnitude from their human hosts. Chemicals that cause cancers in animals seldom do so in humans. For example, in a recent study using rodents, of the thirty-eight chemicals that caused pancreatic cancer and thirty-nine chemicals that caused colorectal cancer in the rodents, none caused cancer in humans.\textsuperscript{147} And a protein that triggers colorectal cancers in animal models was found to suppress cancer growth in humans.\textsuperscript{148} The implication of this finding is frightening, because clinical trials of drugs that deactivate production of this protein would likely stimulate rather than suppress cancer growth, possibly killing patients rather than helping them.

Let’s look back at a success story from cancer research mentioned above—the development and testing of Gleevec (imatinib). Gleevec was developed directly from identification and targeting of a specific genetic mutation that occurs in 95\% of chronic myelogenous leukemia patients, designated the Philadelphia chromosome. But studies of the drug in mice, rats, rabbits, dogs, and monkeys detected serious adverse effects, and in particular, severe liver damage in dogs appeared to preclude clinical trials in

\textsuperscript{144} Hutchinson & Kirk, supra note 120, at 189.


\textsuperscript{146} Begley & Ellis, supra note 140, at 532.

\textsuperscript{147} See Jeffrey W. Card et al., Lack of Human Tissue-Specific Correlations for Rodent Pancreatic and Colorectal Carcinogens, 64 REG. TOXICOLOGY & PHARMACOLOGY 442, 455–56 (2012).

\textsuperscript{148} Wei Tang et al., A Genome-Wide RNAi Screen for Wnt/\beta-Catenin Pathway Components Identifies Unexpected Roles for TCF Transcription Factors in Cancer, 105 PROC. NAT’L ACAD. SCI. 9697, 9697, 9701 (2008).
humans. However, the Novartis research team also conducted studies of the drug in human cell assays and did not identify liver toxicity. Early clinical trials confirmed the absence of significant liver toxicity, and also revealed the pronounced favorable responses of patients to Gleevec, leading to the drug’s 2001 FDA approval to treat chronic myelogenous leukemia. Far from being a success of animal research, Gleevec is a success of rational drug design and human-based drug testing—a life-prolonging success that would have been lost if the results of animal research had prevailed.

But Gleevec is an anomaly, and even other drugs in the same class have failed to prolong survival in various types of cancer. More typical results are the barren twenty-seven years of animal-tested drugs for small-cell lung cancer in more than 10,000 patients, the consistent failures of therapeutic vaccines for melanoma and other cancers, and the persistent failure to cure metastatic cancers. Also more representative of the poor outcomes for cancer therapies is a 2008 review of 624 cancer drugs that progressed to the final (phase III) stage of testing. This review revealed that between 50% and 75% of the drugs fail even at this final stage. And the true failure rate is likely even higher because the review excluded all uncompleted trials and most unreported trials, two additional categories with especially high drug failure rates.

A discouraging and perhaps predictable result of the cancer clinical trial wasteland and its animal research underpinnings is the FDA’s low bar for approval of new cancer drugs. Many, if not most, approvals are for drugs that only impede cancer progression by a few months or a few weeks, may or may not prolong survival, do not cure anyone, commonly cause serious or even lethal adverse effects, and often provide poor quality of life.

152. Steven A. Rosenberg et al., Cancer Immunotherapy: Moving Beyond Current Vaccines, 10 NATURE MED. 909, 913 (2004).
154. See id. at 641.
155. See id. at 632.
at great expense. Tarceva was approved in 2005 to treat pancreatic cancer after a clinical trial claiming to improve median survival by only ten days. Vectibix was approved in 2006 to treat colorectal cancer after a clinical trial that showed a delay of just five days in cancer progression and no prolonged survival. Avastin was approved in 2006 to treat a subgroup of patients with non-small cell lung cancer after showing a survival advantage of two months, and only for men. A later study of Avastin in the same cancer type showed prolonged time to cancer progression of only twelve to eighteen days for the two doses tested. The important difference between a statistical endpoint and meaningful impact on quality of life and survival is now at the forefront, and recommendations include targeting clinical trials toward life-related outcomes. In their review of eighteen clinical trials of FDA-approved cancer drugs since 2000, Ocana and Tannock found that most trials reported minimal advantages in either progression-free interval or overall survival, and none showed as much as five months improved survival.

These and many other cancer drug outcome measures are statistically and objectively dubious, clinically irrelevant, and probably irreproducible—as suggested by the subsequent withdrawal of numerous cancer drugs after post-marketing study data showed that the original clinical trials were wrong and the drugs were not effective after all. Mylotarg was withdrawn for acute myelogenous leukemia treatment in 2010 after a decade on the market. Avastin was withdrawn for breast cancer treatment in 2011 after

---


159. See Cohen et al., supra note 156, at 716.


161. See Ocana & Tannock, supra note 156.

nearly four years on the market. Iressa was withdrawn for lung cancer treatment in 2012 after nine years on the market. And the FDA estimates that when post-marketing studies are performed (this occurs in a minority of approved drugs), more than 10% of cancer drugs are not confirmed to be effective—often several years and sometimes more than a decade after original approval, and after unsuccessful use in many thousands of cancer patients.

In 1999, cancer supplanted heart disease as the leading cause of death among Americans younger than eighty-five years, which is 98% of the U.S. population. By 2008, cancer became the leading cause of death worldwide. The use of animals to study and develop treatments for cancer has consumed enormous resources and several decades without substantially advancing the control and cure of cancer. It frequently happens that cancer researchers gain sterling reputations, career success, and millions of dollars in research funding without helping even one cancer patient gain even one extra day of life. Such is the disconnection between the results of basic science and the needs of human medicine.

This failed animal research paradigm for cancer is openly acknowledged by some cancer researchers. Carlo Maley, Ph.D. of the University of California-San Francisco stated, “We’ve been banging our heads against this cure thing for three, four decades now and really made almost zero progress.” And Bert Vogelstein, M.D., director of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University School of Medicine, adds perspective: “Unfortunately our track record shows that far less than 1 percent of our promising approaches actually make the grade in patients.” More than forty years into the war on cancer, that war is still being lost in animal research laboratories.

165. Peggy Eastman, ODAC Backs FDA’s Strong Stance on Need for Post-Marketing Studies on Accelerated-Approval Cancer Drugs, 33 ONCOLOGY TIMES 8, 9 (2011).
IV. ANIMAL USE IN DRUG DEVELOPMENT AND TESTING

For seventy-five years, the default preclinical testing methods for the efficacy and safety of drugs have relied heavily on the use of animals. Historically based on regulatory responses to two tragic drug-related events, the animal-testing paradigm has nonetheless never been validated to predict or correlate with human outcomes. Former FDA pharmacology and toxicology reviewer Anita O’Connor stated in 1998: “Most of the animal tests we accept have never been validated. They evolved over the past 20 years and the FDA is comfortable with them.”\(^\text{170}\) The deaths of more than 100 persons—many of them children—from taking sulfanilimide elixir in 1937 led to the Federal Food, Drug, and Cosmetic Act of 1938, which among other measures mandated that drugs be shown to be safe before use in humans.\(^\text{171}\) The thalidomide disaster in the late 1950s and early 1960s caused more than 10,000 cases of severe birth deformities in forty-six countries, including seventeen thalidomide-related birth defects in the U.S.\(^\text{172}\) This disaster led to passage of the 1962 Kefauver-Harris Amendments to the Federal Food, Drug, and Cosmetic Act of 1938, which required FDA approval of all drugs before marketing in the U.S., and subsequent FDA regulatory measures established animal experiments as the default method for gaining FDA approval for clinical trials.\(^\text{173}\)

After animal testing identifies an apparently safe and effective drug candidate, and after the FDA approves an Investigational New Drug application, the drug is tested in a series of clinical trials:

♦ **Phase I:** Small trials typically enrolling about ten to 100 healthy volunteers, and designed to assess drug safety and metabolism at various doses. If the drug displays no serious adverse effects, it will usually advance to the next clinical trial phase.

♦ **Phase II:** Larger trials typically enrolling a few hundred patients with the target disease, usually employing a randomized design comparing the drug to placebo or to a comparator drug, and

---


designed to determine if the drug is effective and safe as it is likely to be used in clinical medicine. If this “proof of concept” is successful, the drug will usually advance to the next clinical trial phase.

- **Phase III**: Large final-stage trials before applying for FDA marketing approval, typically enrolling several hundred to several thousand patients with the target disease and employing a randomized design comparing the drug to placebo or to a comparator drug. More detailed information is obtained about drug toxicity.

Drug testing using animals has proven to be very poor for predicting efficacy and toxicities in humans as determined in the subsequent clinical trials. The FDA has reported that the failure rate of drugs tested safe and effective in preclinical studies (including animal tests) is 92%, and current data confirm this very high drug attrition rate. Analyzes of drug failure rates from 2007 to 2010 by Thomson Reuters Life Science Consulting demonstrate that in recent years, the phase II failure rate has increased from 72% to 82%, and the phase III failure rate has increased to 50%. The worsening phase III failure rate has been attributed to the commercially hopeful but scientifically unwise advancement of drugs that show marginal, if any, benefits during phase II trials, and the conclusion is that the 82% phase II failure rate should be even higher. The resulting failure of all but a small percentage of drugs during phase II trials would be a further serious indictment of the animal modeling paradigm because phase II trials are designed to offer proof of the efficacy and safety findings arising primarily from animal studies.

The cumulative clinical trial failure rate was 86% in 1985, increased to 92% by 2003, and continues to increase today, despite all efforts to

---


177. See id.; see also Tamara Elias et al., *Why Products Fail in Phase III*, IN VIVO 1, 5 (2006).

improve the predictability of animal testing. Professor Robin Lovell-Badge of the MRC National Institute for Medical Research, London, calculates the current clinical trials failure rate to be 94%. Recently reported phase-specific data may be even more damning, showing up to a 56% failure rate for phase I, 82% for phase II, and 50% for phase III—a cumulative 96% failure rate.

This pattern of worsening drug candidate attrition is stark evidence that efforts over the past quarter century to improve identification and development of drugs using animal models of human diseases have failed. And why do these drugs fail when tested in humans? Half fail because they simply do not work—efficacy testing in animals was wrong. Another 30% fail because they are unsafe—safety testing in animals was wrong. And 20% fail because they are no better or safer than other available drugs.

Additionally, about half of those few drugs that succeed in clinical trials and receive FDA marketing approval are later relabeled or withdrawn for serious or lethal adverse effects not detected during animal testing. Further, more than 90% of approved drugs work for fewer than half of patients, and response rates (not cures) are as low as 25 to 30% for oncology and neurology drugs.

The FDA classifies at least three-fourths of approved drugs as category S drugs that provide “little or no therapeutic gain” compared to currently available drugs (commonly referred to as “me too” drugs). The
percentage of new drugs that are better or safer than available drugs has been reported elsewhere to be even lower, ranging from just 14% to as low as 11%. The lower figure is confirmed in an often-cited pharmaceutical industry report of all internationally marketed drugs over a two-decade period.

Thus, it takes on average more than 100 drugs that are safe and effective in preclinical testing (including animal testing) to produce just one unique, effective, and safe drug for humans, which then works only in a minority of patients and is not curative for most disease categories. Nor is animal drug safety testing reliable when viewed retrospectively. A recent study found that only 19% of ninety-three serious adverse drug reactions in patients were seen in preclinical animal studies.

There could hardly be stronger cumulative evidence that animal use for drug testing is extremely unreliable and does not contribute to drug efficacy or safety. And the consequences of this translation failure are much worse than just the costs in time and money, because the current animal-based drug testing approach contributes to the approval and widespread use of dangerous drugs. The arthritis drug Vioxx (rofecoxib) was safe in at least eight studies in African green monkeys and five other animal species, but resulted in an estimated 140,000 heart attacks and 60,000 deaths in the U.S.—more American deaths than the Vietnam War. The diabetes drug Avandia (rosiglitazone) was safe in mice, rats, dogs, and monkeys but was reported to increase risks for heart attacks, strokes, heart failure, and

Approved/DrugandBiologicApprovalReports/UCM123957.pdf (stating that the total number of new drug approvals from 2000–2008 was 780, of which 612 (78%) were category S drugs); see also Proposed New Drug, Antibiotic, and Biologic Drug Product Regulations, U.S. FOOD & DRUG ADMIN. (June 9, 1983), http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm119443.htm (commenting on the effectiveness of Type IC drugs, now known as category S).


cardiovascular deaths compared to placebo or other diabetes drugs.\textsuperscript{195} Perhaps as many as 100,000 such events are attributable to Avandia.\textsuperscript{196}

Very instructive is the case of the monoclonal antibody TGN1412, developed to treat B-cell chronic lymphocytic leukemia and arthritis. TGN1412 was tested successfully for safety and efficacy in mice, rats, rabbits, and two species of monkeys.\textsuperscript{197} Yet TGN1412 caused rapid critical immune system activation in all six young men who received the drug in the first stage of clinical testing at London’s Northwick Park Hospital in 2006. This “cytokine storm” was nearly lethal for these healthy volunteers, causing multiple organ failure for all six victims and leading to amputations of toes and fingertips for one participant.\textsuperscript{198} Even though monkey and human TGN1412 binding sites and cellular mechanisms were identical, the hyperactivation of the participants’ immune systems was the opposite of the immune suppression response in monkeys at up to 500 times the dosage tested in the volunteers.\textsuperscript{199} It is difficult to construct a more definitive animal-based prediction of human response and safety, yet all six men have permanent immune system and organ damage.

In the same way that ineffective and dangerous drugs can be approved based on erroneous animal research, useful drugs can also fail animal testing for the same reason. A sterling example is aspirin, which was patented for human use in 1900, decades before animal testing was employed for drugs. When aspirin was later tested for teratogenicity (birth defect causation), it was found to produce birth defects in all eight species tested—mice, rats, guinea pigs, rabbits, cats, dogs, sheep, and monkeys.\textsuperscript{200}

\begin{footnotes}
\item[198] Id. at 1345.
However, aspirin is safe for women during all stages of pregnancy. Similarly, penicillin launched the hugely important antibiotic era in the 1940s and saved countless lives, despite causing birth defects in rats, and killing guinea pigs and hamsters.

The dramatic clinical failures of drugs such as Vioxx and TGN1412, and the falsely alarming animal testing results for drugs such as aspirin and penicillin, demonstrate that no level of certainty from animal testing can reliably predict drug effects in humans. It is just this immutable barrier that led British immunotherapeutics expert David Glover to state: “The relevance of animal testing, whether artificially created disease models or healthy animals for toxicology, has to be very seriously questioned for testing of human-specific biologic drugs,” and former Huntingdon Research Centre scientific director Ralph Heywood to conclude: “Toxicology . . . is a science without a scientific underpinning.”

The reasons for the failed animal testing paradigm for drugs can be traced to the level of genes and gene regulation, but the practical manifestations are revealed at the level of interspecies pharmacology. The five fundamental elements in the science of drug testing are drug absorption, drug distribution in the body, drug metabolism by the liver and other organs, drug elimination from the body, and drug toxicity (collectively labeled ADMET). Some interspecies differences in toxicities have been noted in the foregoing paragraphs, but there are substantial and unresolvable differences between humans and other animals regarding each component of ADMET. One stark example of these differences is that the two human enzymes that metabolize more than 70% of marketed drugs

---

204. Peter Mitchell, Critics Pan Timid European Response to TeGenero Disaster, 25 NATURE BIOTECHNOLOGY 485, 486 (2007).
work very differently in mice, making mice unreliable for testing the safety and efficacy of these and similar drugs.\textsuperscript{206}

Aspirin is again a representative example of the differences in each respective species’ drug metabolism rates that invalidate translation of animal research findings to humans. Aspirin has a half-life in humans of fifteen to twenty minutes (which means that half the drug is eliminated from the circulation in that time period after ingestion), while the active metabolite of aspirin (salicylate) has a half-life of about three hours at standard doses, which extends to as long as thirty hours at high doses.\textsuperscript{207} The aspirin half-life for rats is only eight minutes,\textsuperscript{208} and for dogs and cats it is about eight hours and forty hours, respectively.\textsuperscript{209}

Similarly, the metabolism and related effects of Valium (diazepam) are markedly different for humans and other animals. For example, diazepam half-life in humans is 43±13 hours, which may be as long as 100 hours when active metabolites are considered,\textsuperscript{210} and is prolonged by the minimal contribution of liver metabolism. In contrast, diazepam half-life is less than one hour in dogs, and liver metabolism is rapid and extensive.\textsuperscript{211} Treatment of refractory seizures in dogs may require very large doses of diazepam administered intravenously due to the rapid liver metabolism. The dose required to terminate refractory seizures in a large dog would be lethal for a human. Diazepam half-life is intermediate for cats (five and a half hours), but a single small dose can be lethal due to acute liver necrosis specific for cats.\textsuperscript{212}

So how do these examples compare to the larger picture of drug metabolism in humans and other animals? Interspecies differences in drug metabolism are ubiquitous and are extensively reviewed by Val Beasley,

\begin{itemize}
\item \textsuperscript{207} Aspirin Tablets BP 300mg, DRUGS.COM, http://www.drugs.com/uk/aspirin-tablets-bp-300mg-spc-10476.html (last updated June 10, 2010).
\item \textsuperscript{208} M. Guillaume Wientjes & Gerhard Levy, Nonlinear Pharmacokinetics of Aspirin in Rats, 245 J. PHARMACOLOGY & EXPERIMENTAL THERAPEUTICS 809, 809 (1988).
\item \textsuperscript{209} Specific Nonsteroidal Anti-Inflammatory Drugs, MERCK VETERINARY MANUAL, http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/191606.htm (last updated Mar. 2012); Peter D. Hanson & Jill E. Maddison, Nonsteroidal Anti-Inflammatory Drugs and Chondroprotective Agents, in SMALL ANIMAL CLINICAL PHARMACOLOGY 287, 304 (Jill E. Maddison et al. eds., 2008).
\item \textsuperscript{211} See Barbara Lynn Sherman & Mark G. Papich, Drugs Affecting Animal Behavior, in VETERINARY PHARMACOLOGY AND THERAPEUTICS 509, 519 (Mark G. Papich et al. eds., 9th ed. 2009).
\item \textsuperscript{212} Id.
\end{itemize}
D.V.M., and the absence of correlations is graphically depicted for rodents, dogs, nonhuman primates, and humans in Figure 1.214

Figure 1: Absolute bioavailability of various drugs in dogs (triangles), primates (squares), and rodents (circles) versus the absolute bioavailability reported in humans. Three observations can be made: (i) there is no apparent relationship between animal bioavailability and human bioavailability; (ii) the number of false negatives is high; and (iii) the number of false positives is high.

Moreover, the FDA has acknowledged the inadequacy of animal testing for drug safety in its response to the Institute of Medicine report, The Future of Drug Safety: Promoting and Protecting the Health of the Public, stating: “The FDA is involved in an ongoing scientific collaboration intended to yield more sensitive, specific, and informative tests for drug organ toxicity than the toxicology screening techniques currently in use.”215

But until the FDA eliminates the longstanding—but unvalidated—default status of animal testing for drugs, the pharmaceutical industry is poorly positioned to replace animal tests with human-based methods. As stated by a pharmaceutical company vice president of drug innovation: “[A]nimal models in these disease areas are not predictive, yet regulatory agencies require preclinical investigational new drug (IND) packages to contain in vivo animal efficacy and data based on nonpredictive or nonrelevant disease models.”216

Unfortunately, the FDA appears to be ill-equipped to spearhead the transition from the discredited paradigm of animal testing for drugs to the human-based future of drug testing. A scathing report from its own science board criticized the inadequacy of the FDA’s science expertise for the task of leading and regulating the drug approval process, concluding: “Today, not only can the Agency not lead, it cannot even keep up with the advances in science.”217

V. WHY ANIMAL RESEARCH IS A FAILED PARADIGM AND WHAT SHOULD BE DONE

The straightforward reason that the use of animals to study human diseases and develop drugs is unacceptable is because it has not worked in any predictable, reliable, reproducible, or translatable sense to advance human medicine and conquer human diseases. Some of the evidence for this claim is referenced in the above sections, and reviews of the outcomes of highly touted animal research findings are perhaps definitive on this issue. Contopoulos and colleagues reported the outcomes of 101 highly touted treatments that promised major clinical applications and were published in top basic science journals between 1979 and 1983.218 These “best-of-the-best” treatments were reviewed two decades later, and the findings were both discouraging and revealing: only twenty-seven of the 101 treatments ever advanced to clinical trials, only five were approved for human use, and only one—a blood pressure drug—remains in regular use.
Lindl and colleagues reported the results of citations for published animal research results in Germany for a two-year period. Of ninety-seven such citations, only four made a direct correlation between the animal research results and the clinical findings, and in none of those four instances was the animal research result duplicated.\textsuperscript{219} As also noted above, for the development of safe, effective, and unique drugs, the success rate for even the most promising animal-derived treatments is not more than 1%. This can be called good fortune for that 1%, but it cannot be called science.

Though most promising findings from animal research are not subjected to attempts at replication, those that are scrutinized are frequently markedly modified or even refuted, an outcome termed the Proteus phenomenon.\textsuperscript{220} Often, the initial promising results continually diminish and eventually disappear in later studies,\textsuperscript{221} and the original research is discredited—in many instances only after the erroneous results have been implemented for patients. This is but one explanation for the growing consideration that most breakthrough published medical research is false.\textsuperscript{222}

Decades ago, scientists’ knowledge of comparative biology, physiology, and genetics was inadequate to understand that animals in laboratories are not convenient miniature versions of humans. With the advances achieved in the new millennium—and particularly due to the enormous growth of genetics knowledge resulting from the Human Genome Project and subsequent human and nonhuman animal genetic studies—we now know that the factors that preclude translation of animal research to human benefit reflect differential evolutionary influences. These differences exist at cellular, subcellular, molecular, and submolecular levels. We have learned that interspecies differences in the composition and regulation of genes are both explanatory and immutable regarding the failure of animal research to reliably inform human medicine.

This understanding also explains why the renaissance in medical science promised from the use of genetically modified (GM) animals—

\begin{itemize}
\item \textsuperscript{219} Toni Lindl et al., \emph{Tierversuche in der Biomedizinischen Forschung} [Animal Experiments in Biomedical Research], 22 \textsc{Alternatives to Animal Experimentation} 143, 143 (2005) (Ger.).
\item \textsuperscript{220} John P.A. Ioannidis & Thomas A. Trikalinos, \emph{Early Extreme Contradictory Estimates May Appear in Published Research: The Proteus Phenomenon in Molecular Genetics Research and Randomized Trials}, 58 \textsc{J. Clinical Epidemiology} 543, 547 (2005).
\item \textsuperscript{221} John P.A. Ioannidis, \emph{Evolution and Translation of Research Findings: From Bench to Where?}, \textsc{PLOS Clinical Trials}, e36, Nov. 2006, at 1.
\item \textsuperscript{222} See John P.A. Ioannidis, \emph{Why Most Published Research Findings Are False}, 2 \textsc{PLOS Med.} 696, 696 (2005); John P.A. Ioannidis, \emph{Contradicted and Initially Stronger Effects in Highly Cited Clinical Research}, 294 \textsc{JAMA} 218, 218 (2005); Ramal Moonesinghe et al., \emph{Most Published Research Findings Are False—But a Little Replication Goes a Long Way}, 4 \textsc{PLOS Med.} 218, 218 (2007).
\end{itemize}
predominantly rodents—has not occurred. To the contrary, it has been demonstrated repeatedly that purported gene links to human diseases are often not valid or reproducible and seldom have meaningful effects on disease risk, and that species-specific differences in the regulation of genes invalidate gene-disease associations. Additionally, identical genes often function differently in rodents and humans, and even function differently for genetically identical laboratory animals.

Finally, human identical twins, who are members of the species of interest and share all their genes, nonetheless have different and changing patterns of gene regulation and thus different disease risks and drug responses. The findings arising from the genetics revolution of the last


decade undermine the very premise on which GM animal science is based, and they provide the scientific foundation that should relegate animal research for human diseases and drugs to the historical dustbin. After all, if identical twins are not always reliable predictors for each other, what can we expect to learn from other species about human diseases and drug responses?

The solution to the failed animal research paradigm is of course to replace animal use with research methods that more closely reflect human diseases and drug responses. These methods range from the use of human cells, tissues, and organs to computer-based analysis, advanced imaging, and genetic studies. It is not practical to review these methods in detail here, but a brief mention of some of the available and developing methods follows.

Cultures of human cells and tissues permit many of the cellular and subcellular experiments performed on animals to be performed instead on the species of interest—humans. These may include immortal cell lines, cell and tissue cultures that may be used for personalized approaches to therapy, organotypic cultures that combine cellular elements to replicate tissue and tumor environments, engineered three-dimensional tissue environments, and other constructs. A particularly promising and advancing method is the use of various categories of human stem cells to study human diseases and develop drugs for human use. While these human-based cell and tissue studies will not always replicate results in the “whole animal,” they are more accurate for the questions studied and more translatable than research on the wrong “whole animal.”

Computer-based analysis of the likely efficacy and adverse effects of drugs and chemicals can be performed by a process called QSAR (quantitative structure-activity relationships), which employs large databases of information on human diseases and treatments. The related area of bioinformatics involves the accumulation and sharing of human disease and drug data. Genetic screening and testing techniques such as

---


Microarray methods and pharmacogenomics contribute to patient-specific drug safety and efficacy prediction without using animals. Microdosing is a technique that uses advanced imaging methods to track the metabolism and excretion of drugs administered to humans at doses that are far too small to produce either therapeutic or adverse effects. Its accuracy is such that it has the “ability to detect a liquid compound even after one litre of it has been diluted in the entire oceans of the world.” Already employed by many pharmaceutical companies, microdosing can eliminate the need to obtain such metabolic data from animals, which as discussed earlier is inaccurate anyway.

Microfluidics and related chip technologies permit analysis of human cells and tissues in configurations that mimic cellular, tissue, organ, and whole person scenarios and are widely employed for drug development and toxicity testing for drugs and chemicals. The numerous linked fields of tissue engineering have applications for diagnostics, drug testing, and even culturing and auto-transplantation of tissues or organs. Advanced noninvasive imaging methods such as computed tomography, positron emission tomography, accelerator mass spectrometry, various magnetic resonance imaging methods, ultrasound innovations, and other developing techniques are already replacing animal studies for many research and drug development applications.

238. See generally Nathan Blow, How to Get Ahead in Imaging, 458 NATURE 925, 925 (2009); Vivek Prabhakaran et al., Current Status and Future Perspectives of Magnetic Resonance
More importantly, a shift in emphasis from animal research to human-based methods would accelerate a superior science and hasten the day when basic and applied sciences translate reliably to human medicine. If we knew decades ago what we know now about the failures and consequences of the animal research paradigm, perhaps we would have avoided it and started earlier to develop human-based research methods. But it is often more difficult to undo an erroneous established practice and its accumulated infrastructure than to prevent its adoption in the first place. To the extent that researchers hang on to the old ways, getting there will cost more time, resources, hopes, and human lives.

VI. ANIMAL LAW SHOULD BETTER REFLECT ANIMAL RESEARCH REALITIES

Tying together the brief review of research-related animal law in Section I with the deconstruction of animal research methodology and results in Sections II–IV, the “fatal flaw” of U.S. animal law is evident. While the AWA (poorly) regulates animal treatment and welfare, it does not address the suitability of animal research or seek to define the expectations or goals that “justify” experimentation and the killing of animals in laboratories. The solution is not in the language or intent of the AWA as currently written, and change must come from Congress.

There is evidence of some favorable movement. In December 2011, the Institute of Medicine of the National Academies released its report, *Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity*, in which the need for chimpanzees in the conduct of nearly all biomedical research was dismissed. This IOM report was game-changing for at least three reasons: it was the first federally sponsored report that began to dismantle a major element of animal research, it addressed the use and abuse of our closest genetic relatives, and it granted credibility to opponents of chimpanzee research, who had been kept down by researchers and funding agencies using the bully pulpit to shape public opinion. NIH director Dr. Francis Collins immediately accepted the IOM report’s


conclusions and recommendations, and he commissioned the advisory NIH Council of Councils to develop guidelines for the implementation of the IOM’s recommendations.240

The NIH Council of Councils appointed a Working Group on the Use of Chimpanzees in NIH-Supported Research, which released its report on January 22, 2013, and began a sixty-day public comment period.241 Among the working group’s recommendations are that most current NIH-sponsored chimpanzee research should be ended, that all but a small number of NIH-owned and supported chimpanzees should be retired to sanctuaries, and that very restrictive criteria should be applied to future requests to perform research using chimpanzees.242 On June 26, 2013, Dr. Collins announced that NIH is adopting twenty-seven of the twenty-eight Council of Councils recommendations, excluding a single provision regarding space allocation for chimpanzees.243 It is reasonable to expect that the NIH implementation of the IOM’s recommendations and the Council of Councils’ guidelines will spell the beginning of the end for invasive chimpanzee research in the U.S.

Simultaneously, the Great Ape Protection and Cost Savings Act (GAPCSA) was introduced in both houses of the 112th U.S. Congress (S. 810 and H.R. 1513).244 GAPCSA would establish a timeline to phase out invasive research involving chimpanzees and other great apes, prohibit breeding and transport of great apes for research purposes, and retire all federally owned chimpanzees to sanctuary with lifetime care.245 GAPCSA did not reach a vote in either the Senate or the House of Representatives this session, but the bill will be reintroduced in the 113th Congress.246


246. See PROJECT R&R, supra note 243.
In September 2011, the U.S. Fish & Wildlife Service (FWS) announced that the agency was undertaking a review of the status of captive chimpanzees in the U.S. in response to a petition to reclassify all these chimpanzees from threatened to endangered.\footnote{See Anna Frostic, Humane Soc’y of the U.S., Petition to Upgrade Captive Chimpanzees (\textit{Pan Troglodytes}) from Threatened to Endangered Status Pursuant to the Endangered Species Act of 1973, as Amended 4 (2010), http://www.humanesociety.org/assets/pdfs/animals_laboratories/chimpanzee_research/fws_endangered_petition.pdf; Endangered and Threatened Wildlife and Plants; 90-Day Finding on a Petition to List All Chimpanzees (\textit{Pan Troglodytes}) as Endangered, 76 Fed. Reg. 54,423, 54,423 (Sept. 1, 2011) (notice of petition finding).} In June 2013, FWS announced that it is proposing that all chimpanzees be classified as endangered and further stated that the more than two-decade split-listing of captive chimpanzees was not permitted under the Endangered Species Act of 1973.\footnote{U.S. Fish and Wildlife Service Proposes Protection for All Chimpanzees—Captive and Wild— as Endangered, U.S. FISH & WILDLIFE SERVICE (June 11, 2013), http://www.fws.gov/home/newsroom/serviceproposeschimpanzeesNR06112013.html.} If the proposed reclassification is implemented after a 60-day public comment period, substantial protection of captive chimpanzees from medical research and many other uses will follow. This protection is likely to be enhanced by the announced collaboration between FWS and NIH to coordinate FWS permitting decisions under the Endangered Species Act with NIH research protocol reviews under its new stringent guidelines.

Congress also should consider acting in order to more closely regulate NIH research funding. There is reason to question the science and public health return on investment from the $31 billion NIH discretionary budget, and it is within Congress’s authority to establish guidelines for the NIH regarding the potential returns for public health from the funding of basic science research (more than 40% of the NIH discretionary budget). If Congress is willing to examine and act on the poor returns from animal research and redirect NIH funding to human-based research with the demonstrated potential to improve public health, the road to better science and better medical care will be smoother.